ORBITA‑CTO: Angioplasty Reduces Chest Pain, Boosts QoL in Chronic Total Occlusion

The ORBITA‑CTO trial, presented at ACC.26 and simultaneously published in JACC, shows that percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) meaningfully reduces angina and improves quality of life (QoL) in carefully selected patients. 

In this small, randomized, blinded study, 50 adults with single‑vessel CTO and stable, refractory chest pain were randomly assigned to CTO PCI plus medical therapy or a placebo procedure plus the same medical regimen, with antianginal drugs temporarily stopped and later re‑introduced only as needed.

During a 24‑week follow‑up, patients who underwent CTO PCI had a greater drop in angina symptom scores compared with the placebo group, largely driven by fewer angina episodes. 

On average, treated patients enjoyed about 31 more angina‑free days over 168 days than those in the placebo arm. The CTO‑PCI group also reported better QoL scores and clinicians rated their angina severity as lower, with no deaths, myocardial infarctions, or withdrawals due to worsening symptoms.

The investigators emphasize that in this controlled, blinded design, coronary angioplasty and stenting for CTO clearly improved both symptoms and patient‑reported well‑being over a 6‑month period. 

A related editorial notes that ORBITA‑CTO confirms the benefit of CTO PCI is not just a placebo effect, while underscoring that the magnitude of benefit depends on the individual patient. 

The trial’s small size, highly selected population, and exclusion of the most complex CTOs mean clinicians should use these data as a signal rather than a broad mandate, and future work will need to define precisely which CTO patients gain the most from revascularization.